Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

4.880 +0.030 (+0.62%)
Streaming Delayed Price Updated: 9:37 AM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Puma Biotechnology Reports Second Quarter 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (... 
Via Benzinga
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports First Quarter 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Puma Biotechnology (NASDAQ:PBYI) ... 
Via Benzinga
The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
Puma Biotechnology's Earnings: A Preview
Puma Biotechnology (NASDAQ:PBYI) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Stealth BioTherapeutics (NASDAQ:MITO 
Via Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, investor! We're starting off the day right with a look at the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
20 Stocks Moving in Thursday's Pre-Market Session
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-... 
Via Benzinga
Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biomerica (NASDAQ:BMRA) stock inc... 
Via Benzinga
Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.